[go: up one dir, main page]

ATE147634T1 - Produkte zur behandlung des endotoxin -schocks bei einem säugetier - Google Patents

Produkte zur behandlung des endotoxin -schocks bei einem säugetier

Info

Publication number
ATE147634T1
ATE147634T1 AT89121661T AT89121661T ATE147634T1 AT E147634 T1 ATE147634 T1 AT E147634T1 AT 89121661 T AT89121661 T AT 89121661T AT 89121661 T AT89121661 T AT 89121661T AT E147634 T1 ATE147634 T1 AT E147634T1
Authority
AT
Austria
Prior art keywords
mammal
products
endotoxin shock
effective amount
therapeutically effective
Prior art date
Application number
AT89121661T
Other languages
English (en)
Inventor
Allan Wissner
Suresh S Kerwar
Constance Kohler
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE147634T1 publication Critical patent/ATE147634T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Surgical Instruments (AREA)
  • Percussive Tools And Related Accessories (AREA)
  • Disintegrating Or Milling (AREA)
  • Thermistors And Varistors (AREA)
  • Measurement Of Force In General (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
AT89121661T 1988-12-19 1989-11-23 Produkte zur behandlung des endotoxin -schocks bei einem säugetier ATE147634T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28620188A 1988-12-19 1988-12-19

Publications (1)

Publication Number Publication Date
ATE147634T1 true ATE147634T1 (de) 1997-02-15

Family

ID=23097534

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89121661T ATE147634T1 (de) 1988-12-19 1989-11-23 Produkte zur behandlung des endotoxin -schocks bei einem säugetier

Country Status (18)

Country Link
US (1) US5124147A (de)
EP (1) EP0374510B1 (de)
JP (1) JP2931344B2 (de)
KR (1) KR0148680B1 (de)
AT (1) ATE147634T1 (de)
AU (1) AU624457B2 (de)
CA (1) CA2005670A1 (de)
DE (1) DE68927671T2 (de)
DK (1) DK641889A (de)
ES (1) ES2096553T3 (de)
FI (1) FI896046A0 (de)
GR (1) GR3022969T3 (de)
IL (1) IL92471A (de)
NZ (1) NZ231725A (de)
PH (1) PH31376A (de)
PT (1) PT92596B (de)
SG (1) SG43205A1 (de)
ZA (1) ZA899685B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5147864A (en) * 1988-12-19 1992-09-15 American Cyanamid Company Bis-arylphosphate ester antagonists of platelet activating factor
US4983592A (en) * 1988-12-19 1991-01-08 American Cyanamid Co. Bis-arylphosphate ester antagonists of platelet activating factor
US5231091A (en) * 1988-12-19 1993-07-27 American Cyanamid Company Bis-arylphosphate ester antagonists of platelet activating factor
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
AU3244693A (en) * 1991-12-17 1993-07-19 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
US5733742A (en) 1993-06-03 1998-03-31 Therapeutic Antibodies Inc. Production of antibody fragments from whole blood
IL110787A0 (en) * 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
AU1518595A (en) * 1994-01-14 1995-08-01 Genentech Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
CA2185162A1 (en) 1994-03-07 1995-09-14 Robert F. Halenback (Deceased) Compositions for the inhibition of tnf formation and uses thereof
US5939269A (en) * 1994-12-28 1999-08-17 The Regents Of The University Of California Antagonists to insulin receptor tyrosine kinase inhibitor
EP0813423B1 (de) * 1995-01-23 2002-07-03 Xenotech Incorporated Zusammensetzung zur verhinderung von osteolyse und metastasen
GB2304342A (en) * 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
US20020025316A1 (en) * 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US7566772B2 (en) 2005-01-26 2009-07-28 Amgen Fremont Inc. Antibodies against interleukin-1β
CN101500607B (zh) 2005-05-16 2013-11-27 阿布维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
US7863426B2 (en) 2006-04-05 2011-01-04 Abbott Biotechnology Ltd. Antibody purification
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20100329983A1 (en) 2009-06-26 2010-12-30 Soricimed Biopharma Inc. Compounds and methods for the detection of trpv-6 cancers and drug delivery
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (de) 2015-04-10 2016-10-12 Ares Trading S.A. Induktionsdosierschema zur behandlung von krankheiten die von tnf alpha verursacht sind
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148879A (en) * 1977-12-23 1979-04-10 Nelson Research & Development Company Inhibition of platelet aggregation with selected phosphonic and phosphinic acid esters

Also Published As

Publication number Publication date
DE68927671D1 (de) 1997-02-27
JP2931344B2 (ja) 1999-08-09
KR0148680B1 (ko) 1998-08-17
PT92596B (pt) 1996-06-28
IL92471A (en) 1995-06-29
JPH02212435A (ja) 1990-08-23
EP0374510B1 (de) 1997-01-15
AU624457B2 (en) 1992-06-11
AU4688589A (en) 1990-06-21
DK641889D0 (da) 1989-12-18
ZA899685B (en) 1990-09-26
SG43205A1 (en) 1997-10-17
PT92596A (pt) 1990-06-29
NZ231725A (en) 1992-12-23
DE68927671T2 (de) 1997-05-07
PH31376A (en) 1998-10-29
EP0374510A1 (de) 1990-06-27
CA2005670A1 (en) 1990-06-19
DK641889A (da) 1990-06-20
US5124147A (en) 1992-06-23
GR3022969T3 (en) 1997-06-30
KR900009097A (ko) 1990-07-02
FI896046A0 (fi) 1989-12-18
IL92471A0 (en) 1990-08-31
ES2096553T3 (es) 1997-03-16

Similar Documents

Publication Publication Date Title
ATE147634T1 (de) Produkte zur behandlung des endotoxin -schocks bei einem säugetier
ATE172880T1 (de) Verwendung von monoklonalen anti-tnf-antikörpern für die behandlung von bakteriellen meningitiden
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
EP0481970A3 (en) Monoclonal antibodies against endotoxin of gram-negative bacteria
DK0492448T3 (da) Monoklonale antistoffer mod human tumor-nekrotiserende faktor alfa
DK149990D0 (da) Familie af modificerede antistoffer med hoej affinitet til cancerbehandling
ATE101876T1 (de) Verfahren zur verringerung der heterogenitaet von monoklonalen antikoerpern.
ATE93144T1 (de) Methode zur verminderung der immunglobulin-ereaktion.
DE69024279D1 (de) Cytokine
IT1231727B (it) Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
DE68911653D1 (de) Antagonist für Interleukin-5 zur Verhütung oder Verminderung von Eosinophilie.
GB2254326B (en) Monoclonal antibodies produced by in vitro immunization of lymphocytes
FI922551A0 (fi) Foerfarande foer skoetsel av septisk chock.
DK717888A (da) Monoklonale antistoffer
DK592086A (da) Humant conglutinin
IT1163911B (it) Resina per lenti di elevata rifrattivita' e lenti prodotte con la resina stessa
FI924278A0 (fi) Bcrf1 antagonister foer skoetsel av epstein-barr-virusinfektioner.
FI925638A0 (fi) Monoklonal antikropp 88bv59 riktad mot en i samband med tumoerer foerekommande antigen
CS512290A3 (en) Mouse hybridoma ifna1-118 producing monoclonal antibody binding the human interferon alpha 1
CS511090A3 (en) Mouse hybridoma ifna2-n10 producing monoclonal antibody binding the human interferon alpha 2
NO841466L (no) Neutron-kilde av akseleratortypen og fremgangsmaate for styring av denne.
RO79592A2 (ro) Compozitie pentru tratamentul sistemic al bolii venoase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee